|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/23 Celldex Therapeutics, Inc. 10-K 12/31/22 85:8.1M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.20M
2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 30K
3: EX-21.1 Subsidiaries List HTML 24K
4: EX-23.1 Consent of Expert or Counsel HTML 23K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
7: EX-32 Certification -- §906 - SOA'02 HTML 26K
13: R1 Document and Entity Information HTML 93K
14: R2 Consolidated Balance Sheets HTML 117K
15: R3 Consolidated Balance Sheets (Parenthetical) HTML 40K
16: R4 Consolidated Statements of Operations and HTML 96K
Comprehensive Loss
17: R5 Consolidated Statements of Stockholders Equity HTML 67K
18: R6 Consolidated Statements of Cash Flows HTML 99K
19: R7 Nature of Business and Overview HTML 28K
20: R8 Summary of Significant Accounting Policies HTML 62K
21: R9 Accumulated Other Comprehensive Income HTML 46K
22: R10 Fair Value Measurements HTML 95K
23: R11 Marketable Securities HTML 103K
24: R12 Property and Equipment, Net HTML 44K
25: R13 Leases HTML 33K
26: R14 Intangible Assets HTML 27K
27: R15 Accrued Expenses HTML 38K
28: R16 Other Long-Term Liabilities HTML 42K
29: R17 Stockholders' Equity HTML 31K
30: R18 Stock-Based Compensation HTML 82K
31: R19 Revenue HTML 30K
32: R20 Collaboration Agreements HTML 26K
33: R21 Income Taxes HTML 110K
34: R22 Retirement Savings Plan HTML 28K
35: R23 Kolltan Acquisition HTML 32K
36: R24 Summary of Significant Accounting Policies HTML 112K
(Policies)
37: R25 Summary of Significant Accounting Policies HTML 32K
(Tables)
38: R26 Accumulated Other Comprehensive Income (Tables) HTML 45K
39: R27 Fair Value Measurements (Tables) HTML 95K
40: R28 Marketable Securities (Tables) HTML 102K
41: R29 Property and Equipment, Net (Tables) HTML 43K
42: R30 Leases (Tables) HTML 31K
43: R31 Accrued Expenses (Tables) HTML 38K
44: R32 Other Long-Term Liabilities (Tables) HTML 41K
45: R33 Stock-Based Compensation (Tables) HTML 80K
46: R34 Income Taxes (Tables) HTML 108K
47: R35 Nature of Business and Overview (Details) HTML 32K
48: R36 Summary of Significant Accounting Policies - Basis HTML 24K
of Presentation (Details)
49: R37 Summary of Significant Accounting Policies - HTML 32K
Concentration of Credit Risk and Significant
Customers and Suppliers (Details)
50: R38 Summary of Significant Accounting Policies - HTML 35K
Property and Equipment (Details)
51: R39 Summary of Significant Accounting Policies - HTML 32K
Leases (Details)
52: R40 Summary of Significant Accounting Policies - HTML 26K
Foreign Currency Translation (Details)
53: R41 Summary of Significant Accounting Policies - Net HTML 27K
Loss Per Share (Details)
54: R42 Accumulated Other Comprehensive Income (Details) HTML 45K
55: R43 Fair Value Measurements (Details) HTML 44K
56: R44 Fair Value Measurements - Contingent Consideration HTML 31K
Liabilities (Details)
57: R45 Fair Value Measurements - Additional information HTML 44K
(Details)
58: R46 Marketable Securities (Details) HTML 62K
59: R47 Marketable Securities - Additional Information HTML 26K
(Details)
60: R48 Property and Equipment, Net (Details) HTML 47K
61: R49 Leases (Details) HTML 49K
62: R50 Leases - Future minimum lease payments under HTML 35K
non-cancellable leases (Details)
63: R51 Intangible Assets (Details) HTML 32K
64: R52 Accrued Expenses (Details) HTML 33K
65: R53 Other Long-Term Liabilities (Details) HTML 37K
66: R54 Other Long-Term Liabilities- New Jersey tax HTML 34K
benefits (Details)
67: R55 Stockholders' Equity (Details) HTML 42K
68: R56 Stock-Based Compensation - Employee Stock Purchase HTML 36K
Plan (Details)
69: R57 Stock-Based Compensation - Employee Stock Option HTML 56K
and Incentive Plan (Details)
70: R58 Stock-Based Compensation - Stock Option Activity HTML 69K
(Details)
71: R59 Stock-Based Compensation - Expenses (Details) HTML 29K
72: R60 Stock-Based Compensation - Valuation (Details) HTML 42K
73: R61 Revenue (Details) HTML 46K
74: R62 Collaboration Agreements (Details) HTML 30K
75: R63 Income Taxes - Benefit (Provision) (Details) HTML 38K
76: R64 Income Taxes - Reconciliation (Details) HTML 48K
77: R65 Income Taxes - Summary of deferred tax assets and HTML 48K
liabilities (Details)
78: R66 Income Taxes - Carryforwards (Details) HTML 44K
79: R67 Retirement Savings Plan (Details) HTML 30K
80: R68 Kolltan Acquisition (Details) HTML 41K
83: XML IDEA XML File -- Filing Summary XML 154K
81: XML XBRL Instance -- cldx-20221231x10k_htm XML 1.63M
82: EXCEL IDEA Workbook of Financial Reports XLSX 134K
9: EX-101.CAL XBRL Calculations -- cldx-20221231_cal XML 173K
10: EX-101.DEF XBRL Definitions -- cldx-20221231_def XML 509K
11: EX-101.LAB XBRL Labels -- cldx-20221231_lab XML 1.24M
12: EX-101.PRE XBRL Presentations -- cldx-20221231_pre XML 862K
8: EX-101.SCH XBRL Schema -- cldx-20221231 XSD 152K
84: JSON XBRL Instance as JSON Data -- MetaLinks 398± 641K
85: ZIP XBRL Zipped Folder -- 0001104659-23-026701-xbrl Zip 479K
Exhibit 32
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Celldex Therapeutics, Inc. (the “Company”), that, to his knowledge, the Annual Report of the Company on Form 10-K for the period ended December 31, 2022 (the “Form 10-K”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Form 10-K. A signed original of this statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
| | |
Date: February 28, 2023 | By: | |
| | Name: Anthony S. Marucci |
| | Title: President and Chief Executive Officer |
8 | | |
Date: February 28, 2023 | By: | /s/ SAM MARTIN |
| | Name: Sam Martin |
| | Title: Senior Vice President and Chief Financial Officer |
This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/28/23 | 8-K | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/24 Celldex Therapeutics, Inc. 424B5 2:415K Toppan Merrill/FA 2/28/24 Celldex Therapeutics, Inc. 424B5 1:377K Toppan Merrill/FA 2/26/24 Celldex Therapeutics, Inc. 10-K 12/31/23 87:8.5M Toppan Merrill/FA2 2/26/24 Celldex Therapeutics, Inc. 424B5 2:352K Toppan Merrill/FA 11/08/23 Celldex Therapeutics, Inc. 424B5 2:476K Toppan Merrill/FA 11/07/23 Celldex Therapeutics, Inc. 424B5 1:439K Toppan Merrill/FA 11/03/23 Celldex Therapeutics, Inc. S-3ASR 11/03/23 4:275K Toppan Merrill/FA 6/21/23 Celldex Therapeutics, Inc. S-8 6/21/23 4:69K Toppan Merrill/FA |